References
- FDA CDx definition. Available from: www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm
- Agarwal A, Ressler D, Snyder G. The current and future state of companion diagnostics. Pharmgenomics Pers Med 2015;8:99-110
- Batrla R, Jordan BW. Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics. Ann N Y Acad Sci 2015;1346(1):71-80
- Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108(2):171-82
- Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474(7353):609-15
- Lynparza package insert. Wilmington DE: AstraZeneca Pharmaceuticals LP; 2014
- FDA press release. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm
- Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366(15):1382-92
- Ledermann J, Harter P, Gourley C. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15(8):852-61
- Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. J Clin Oncol 2015;33(3):244-50
- Summary of Safety and Efficacy Data. Available from: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm?num=p140020
- Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008;105(44):17079-84
- McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66(16):8109-15
- Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20(3):764-75
- BRACAnalysis Post Market Approval. Available from: www.accessdata.fda.gov/cdrh_docs/pdf14/P140020a.pdf
- Olaparib maintenance monotherapy in patients with BRCA mutated ovarian cancer following first line platinum based chemotherapy. (SOLO-1). Available from: https://clinicaltrials.gov/ct2/show/NCT01844986
- Olaparib treatment in BRCA mutated ovarian cancer patients after complete or partial response to platinum chemotherapy. Available from: https://clinicaltrials.gov/ct2/show/NCT01874353
- NCCN guidelines. Available from: www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
- BRACAnalysis CDx Technical Use. Available from: https://myriad-library.s3.amazonaws.com/technical-specifications/BRACAnalysis_CDx_Tech_Specs.pdf